免疫治疗后病理缓解与转移性肾细胞癌延迟肾切除术患者生存相关
本回顾性研究纳入60例接受含免疫检查点抑制剂方案后行巩固性肾切除术的转移性肾细胞癌患者,评估影像学与病理学肿瘤缓解与生存的关系。主要病理缓解(残留存活肿瘤<10%)与无进展生存和总生存显著相关,而影像学原发灶缓解的保护作用未达统计学显著。
要点
- 免疫治疗后肾切除标本主要病理缓解(残留存活肿瘤<10%)与更长的PFS和OS显著相关。
- 原发灶影像学缓解与PFS或OS的保护性关联未达统计学显著。
- 术后病理缓解有助于指导肾切除后治疗时机与序贯策略。
核心结论
- 肾切除时达到主要病理缓解的患者PFS和OS更长。
- 病理缓解有助于指导肾切除后治疗时机与序贯,但需未来研究进一步验证免疫治疗后病理终点的效用。
研究设计与样本
- 回顾性研究,在高容量学术中心识别2015至2024年间接受至少一种含免疫治疗方案后行巩固性肾切除术的转移性肾细胞癌患者60例。
- 影像学缓解采用实体瘤疗效评价标准评估,病理缓解采用残留存活肿瘤百分比衡量,主要病理缓解定义为残留存活肿瘤<10%。
- 采用Cox比例风险模型分析无进展生存和总生存。
主要发现
- 60例患者接受免疫治疗后巩固性肾切除术,肾切除中位时间9个月(四分位距:7,14),2年OS率为75%(95%CI:60-85%)。
- 15例(26%)达到主要病理缓解,21例(35%)原发肿瘤达到影像学缓解。
- 影像学缓解为保护性但未与PFS或OS显著相关;主要病理缓解与PFS显著相关(HR:0.05,95%CI:0.01-0.41;p=0.005)并与OS显著相关(HR:0.07,95%CI:0.01-0.88;p=0.039)。
关键数值与推荐
- 主要病理缓解定义为残留存活肿瘤<10%。
- 主要病理缓解与PFS相关:HR 0.05(95%CI 0.01-0.41),p=0.005。
- 主要病理缓解与OS相关:HR 0.07(95%CI 0.01-0.88),p=0.039。
- 2年OS率75%(95%CI:60-85%),肾切除中位时间9个月(四分位距:7,14)。
临床怎么用
- 肾切除标本病理缓解评估可用于识别免疫治疗后获益更大的患者。
- 病理缓解结果可辅助制定肾切除后治疗时机与序贯策略。
局限性
- 为单中心回顾性研究,样本量60例。
- 免疫治疗后病理终点的效用尚需未来研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The role of consolidative nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors remains unknown. As patients derive variable benefit from immunotherapy (IO), an understanding of how treatment response is associated with long-term outcomes could inform patient surgical selection. We thus conducted a retrospective study to evaluate whether radiographic and pathologic tumor responses after IO are associated with survival in patients undergoing CN at a high-volume academic center. METHODS: We identified mRCC patients treated with at least one IO-containing regimen followed by CN between 2015 and 2024. A radiographic response was assessed using the Response Evaluation Criteria in Solid Tumors. A pathologic response was measured using the percentage of residual viable tumor (RVT), with a major pathologic response (MPR) defined as RVT <10%. Outcomes included progression-free (PFS) and overall (OS) survival, analyzed using Cox proportional hazards models. KEY FINDINGS AND LIMITATIONS: Sixty patients underwent CN after IO. The median time to nephrectomy was 9 mo (interquartile range: 7, 14), and the 2-yr OS rate was 75% (95% confidence interval [CI]: 60-85%). Fifteen patients (26%) had an MPR and 21 patients (35%) had a radiographic response of the primary tumor. The radiographic response was protective but not significantly associated with PFS or OS. The MPR was significantly associated with PFS (hazard ratio [HR]: 0.05, 95% CI: 0.01-0.41; p = 0.005) and OS (HR: 0.07, 95% CI: 0.01-0.88; p = 0.039). CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients with an MPR at nephrectomy had longer PFS and OS. A pathologic response helps guide postnephrectomy treatment timing and sequencing, although future efforts should further validate the utility of post-IO pathologic endpoints.
引用
- Khandwala YS, Reese SW, Ucpinar BA, et al. Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 2025. PMID: 41309336. doi:10.1016/j.euo.2025.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。